Arrivent Biopharma inc (AVBP) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access AVBP Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Arrivent Biopharma inc balances growth, leverage, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent154.68
Short-term Investments, Total218.72
Cash & Short-term Investments372.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current23.75
Total Current Assets394.17
Long-term investments0.00
Deferred Costs, Noncurrent AS0.04
Other Assets, Noncurrent0.50
Operating Lease Right Of Use Asset0.37
Total Assets394.72
Liabilities
Accounts Payable, Current AC2.22
Accrued Liabilities, Current AC25.31
Other Liabilities, Current0.32
Total Current Liabilities27.84
Total Long-term Debt0.00
Other liabilities, Noncurrent0.03
OperatingLeaseLiabilityNoncurrent0.32
Operating Lease Liability Current0.10
Total Liabilities27.88
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock864.96
Retained Earnings / Accumulated Deficit-497.85
Accumulated Other Comprehensive Income-0.27
Other Equity-0.27
Common Stockholder's Equity366.84
Total Stockholder's Equity366.84
Liabilities & Stockholder's Equity394.72
4 historic quarters locked

Sign in to unlock the full Arrivent Biopharma inc balance sheet history.

About Arrivent Biopharma Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-26-094902

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.